每日两次及四次齐多夫定对疾病控制中心II/III期患者p24抗原血症的影响。
The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.
作者信息
Gill S, Tang A, Cordery M, Spacey B, Kelly G, Bateman N T, Barlow D
机构信息
Department of GU Medicine, St Thomas' Hospital, London.
出版信息
Genitourin Med. 1991 Feb;67(1):15-7. doi: 10.1136/sti.67.1.15.
Abstract
Reduction of HIV p24 antigenaemia by zidovudine was investigated in 34 HIV antibody-positive, asymptomatic patients in a randomised, double-blind, placebo-controlled trial. Zidovudine was shown to lower p24 antigen levels as effectively when administered twice daily as when administered four times daily. Serum levels of p24 antigen varied little over 18 weeks in patients taking placebo.
摘要
在一项随机、双盲、安慰剂对照试验中，对34名HIV抗体阳性的无症状患者研究了齐多夫定降低HIV p24抗原血症的效果。结果显示，齐多夫定每日给药两次与每日给药四次时降低p24抗原水平的效果相同。服用安慰剂的患者在18周内p24抗原的血清水平变化不大。
相似文献
1
The effects of twice and four times daily zidovudine on p24 antigenaemia in CDC stage II/III patients.
Genitourin Med. 1991 Feb;67(1):15-7. doi: 10.1136/sti.67.1.15.
2
Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
AIDS. 1994 Mar;8(3):313-21. doi: 10.1097/00002030-199403000-00004.
3
Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group.
Br J Haematol. 1994 Jan;86(1):174-9. doi: 10.1111/j.1365-2141.1994.tb03270.x.
4
5
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
N Engl J Med. 1990 Apr 5;322(14):941-9. doi: 10.1056/NEJM199004053221401.
6
7
The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDS-related complex.
AIDS. 1992 Aug;6(8):821-5. doi: 10.1097/00002030-199208000-00009.
8
The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
J Acquir Immune Defic Syndr (1988). 1994 Feb;7(2):139-47.
9
10
Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS.
AIDS Res Hum Retroviruses. 1995 Apr;11(4):473-9. doi: 10.1089/aid.1995.11.473.
引用本文的文献
1
Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy.
BMJ. 2002 Mar 30;324(7340):757. doi: 10.1136/bmj.324.7340.757.
2
Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.
Pharmacoeconomics. 1993 Apr;3(4):309-37. doi: 10.2165/00019053-199303040-00006.
本文引用的文献
1
Anemia and erythropoiesis in patients with the acquired immunodeficiency syndrome (AIDS) and Kaposi sarcoma treated with zidovudine.
Ann Intern Med. 1988 Mar;108(3):372-6. doi: 10.7326/0003-4819-108-3-372.
2
Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.
Arch Intern Med. 1988 Oct;148(10):2151-3.
3
Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT).
Ann Intern Med. 1988 Feb;108(2):175-80. doi: 10.7326/0003-4819-108-2-175.
4
Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS.
Br Med J (Clin Res Ed). 1986 Dec 6;293(6560):1459-62. doi: 10.1136/bmj.293.6560.1459.
5
Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects.
Lancet. 1988 Feb 20;1(8582):373-6. doi: 10.1016/s0140-6736(88)91179-8.
6
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.
N Engl J Med. 1989 Sep 14;321(11):726-38. doi: 10.1056/NEJM198909143211106.
7
Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.
AIDS. 1989 Sep;3(9):555-61. doi: 10.1097/00002030-198909000-00001.
8
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
Ann Intern Med. 1990 May 15;112(10):727-37. doi: 10.7326/0003-4819-112-10-727.
9
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
N Engl J Med. 1990 Apr 5;322(14):941-9. doi: 10.1056/NEJM199004053221401.
Zotero 插件